Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study.
adverse events of interest
computerized medical record systems
influenza
influenza vaccines
sentinel surveillance
Journal
JMIR public health and surveillance
ISSN: 2369-2960
Titre abrégé: JMIR Public Health Surveill
Pays: Canada
ID NLM: 101669345
Informations de publication
Date de publication:
28 03 2022
28 03 2022
Historique:
received:
16
11
2020
accepted:
29
03
2021
revised:
18
03
2021
entrez:
28
3
2022
pubmed:
29
3
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Vaccination is the most effective form of prevention of seasonal influenza; the United Kingdom has a national influenza vaccination program to cover targeted population groups. Influenza vaccines are known to be associated with some common minor adverse events of interest (AEIs), but it is not known if the adjuvanted trivalent influenza vaccine (aTIV), first offered in the 2018/2019 season, would be associated with more AEIs than other types of vaccines. We aim to compare the incidence of AEIs associated with different types of seasonal influenza vaccines offered in the 2018/2019 season. We carried out a retrospective cohort study using computerized medical record data from the Royal College of General Practitioners Research and Surveillance Centre sentinel network database. We extracted data on vaccine exposure and consultations for European Medicines Agency-specified AEIs for the 2018/2019 influenza season. We used a self-controlled case series design; computed relative incidence (RI) of AEIs following vaccination; and compared the incidence of AEIs associated with aTIV, the quadrivalent influenza vaccine, and the live attenuated influenza vaccine. We also compared the incidence of AEIs for vaccinations that took place in a practice with those that took place elsewhere. A total of 1,024,160 individuals received a seasonal influenza vaccine, of which 165,723 individuals reported a total of 283,355 compatible symptoms in the 2018/2019 season. Most AEIs occurred within 7 days following vaccination, with a seasonal effect observed. Using aTIV as the reference group, the quadrivalent influenza vaccine was associated with a higher incidence of AEIs (RI 1.46, 95% CI 1.41-1.52), whereas the live attenuated influenza vaccine was associated with a lower incidence of AEIs (RI 0.79, 95% CI 0.73-0.83). No effect of vaccination setting on the incidence of AEIs was observed. Routine sentinel network data offer an opportunity to make comparisons between safety profiles of different vaccines. Evidence that supports the safety of newer types of vaccines may be reassuring for patients and could help improve uptake in the future.
Sections du résumé
BACKGROUND
Vaccination is the most effective form of prevention of seasonal influenza; the United Kingdom has a national influenza vaccination program to cover targeted population groups. Influenza vaccines are known to be associated with some common minor adverse events of interest (AEIs), but it is not known if the adjuvanted trivalent influenza vaccine (aTIV), first offered in the 2018/2019 season, would be associated with more AEIs than other types of vaccines.
OBJECTIVE
We aim to compare the incidence of AEIs associated with different types of seasonal influenza vaccines offered in the 2018/2019 season.
METHODS
We carried out a retrospective cohort study using computerized medical record data from the Royal College of General Practitioners Research and Surveillance Centre sentinel network database. We extracted data on vaccine exposure and consultations for European Medicines Agency-specified AEIs for the 2018/2019 influenza season. We used a self-controlled case series design; computed relative incidence (RI) of AEIs following vaccination; and compared the incidence of AEIs associated with aTIV, the quadrivalent influenza vaccine, and the live attenuated influenza vaccine. We also compared the incidence of AEIs for vaccinations that took place in a practice with those that took place elsewhere.
RESULTS
A total of 1,024,160 individuals received a seasonal influenza vaccine, of which 165,723 individuals reported a total of 283,355 compatible symptoms in the 2018/2019 season. Most AEIs occurred within 7 days following vaccination, with a seasonal effect observed. Using aTIV as the reference group, the quadrivalent influenza vaccine was associated with a higher incidence of AEIs (RI 1.46, 95% CI 1.41-1.52), whereas the live attenuated influenza vaccine was associated with a lower incidence of AEIs (RI 0.79, 95% CI 0.73-0.83). No effect of vaccination setting on the incidence of AEIs was observed.
CONCLUSIONS
Routine sentinel network data offer an opportunity to make comparisons between safety profiles of different vaccines. Evidence that supports the safety of newer types of vaccines may be reassuring for patients and could help improve uptake in the future.
Identifiants
pubmed: 35343907
pii: v8i3e25803
doi: 10.2196/25803
pmc: PMC9002594
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25803Informations de copyright
©Simon de Lusignan, Ruby S M Tsang, Oluwafunmi Akinyemi, Jamie Lopez Bernal, Gayatri Amirthalingam, Julian Sherlock, Gillian Smith, Maria Zambon, Gary Howsam, Mark Joy. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 28.03.2022.
Références
Hum Vaccin Immunother. 2018 Mar 4;14(3):706-711
pubmed: 29303681
JMIR Public Health Surveill. 2020 Jul 2;6(3):e19773
pubmed: 32484782
Vaccine. 2020 May 8;38(22):3869-3880
pubmed: 32299719
Stat Methods Med Res. 2009 Feb;18(1):7-26
pubmed: 18562396
BMJ Open. 2016 Apr 20;6(4):e011092
pubmed: 27098827
JMIR Public Health Surveill. 2020 Apr 2;6(2):e18606
pubmed: 32240095
Vaccine. 2018 Jul 5;36(29):4207-4214
pubmed: 29885773
BMJ. 2020 Aug 14;370:m3226
pubmed: 32816716
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
Hum Vaccin Immunother. 2019;15(5):1048-1059
pubmed: 30648923
Adv Ther. 2018 Aug;35(8):1199-1214
pubmed: 29995300
Am J Epidemiol. 2013 Oct 1;178(7):1139-45
pubmed: 23863759
Hum Vaccin Immunother. 2020 Sep 1;16(9):2238-2244
pubmed: 32040379
BMJ Open. 2016 Sep 20;6(9):e011948
pubmed: 27650763
BMJ. 2017 Nov 9;359:j5084
pubmed: 29122753
Rev Esp Quimioter. 2019 Aug;32(4):288-295
pubmed: 31232571
Stat Med. 2006 May 30;25(10):1768-97
pubmed: 16220518
BMJ. 2016 Sep 12;354:i4515
pubmed: 27618829
Clin Infect Dis. 2003 Mar 15;36(6):705-13
pubmed: 12627354
J Allergy Clin Immunol. 2016 Mar;137(3):868-78
pubmed: 26452420
Vaccine. 2014 Sep 3;32(39):5027-34
pubmed: 25045825
BMJ Open. 2017 May 17;7(5):e015469
pubmed: 28515198